|
Aug 13
|
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
|
|
Aug 13
|
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
|
|
Aug 12
|
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
|
|
Aug 12
|
Quantified Named to 2025 Inc. 5000, One of the 50 Fastest-Growing AI Firms in the U.S.
|
|
Aug 12
|
Novartis scores again with third ianalumab Phase III victory
|
|
Aug 12
|
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda
|
|
Aug 12
|
Novartis shares slightly up after Ianalumab meets goals in Phase 3 trial
|
|
Aug 12
|
Novartis’s Ianalumab Meets Goals in Phase 3 Trial to Treat Autoimmune Disease
|
|
Aug 12
|
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
|
|
Aug 11
|
Sector Update: Health Care Stocks Rise Late Afternoon
|
|
Aug 11
|
Market Chatter: Novartis, Roche Executives to Meet With Swiss Government About US Tariffs
|
|
Aug 11
|
Novartis’ mAb could become first Sjögren’s disease drug after Phase III success
|
|
Aug 11
|
Barrick Mining, Rheinmetall, Novartis: Global Stocks in Focus
|
|
Aug 11
|
Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease
|
|
Aug 11
|
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
|
|
Aug 9
|
How Switzerland’s tariff drama swung from hope to despair
|
|
Aug 8
|
Switzerland says tariff talks with US continue, gold industry concerned about bullion trade
|
|
Aug 8
|
Chronic Obstructive Pulmonary Disease Treatment Devices Market Insights, Competitive Landscape, and Market Forecast 2024-2032
|
|
Jul 29
|
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
|
|
Jul 29
|
Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival
|